PL2848258T3 - Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta - Google Patents

Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta

Info

Publication number
PL2848258T3
PL2848258T3 PL14191582T PL14191582T PL2848258T3 PL 2848258 T3 PL2848258 T3 PL 2848258T3 PL 14191582 T PL14191582 T PL 14191582T PL 14191582 T PL14191582 T PL 14191582T PL 2848258 T3 PL2848258 T3 PL 2848258T3
Authority
PL
Poland
Prior art keywords
treatment
mediterranean fever
familial mediterranean
1beta antibodies
1beta
Prior art date
Application number
PL14191582T
Other languages
English (en)
Inventor
Phil Lowe
Hermann Gram
Thomas Jung
Timothy Wright
Trevor Mundel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2848258(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2848258T3 publication Critical patent/PL2848258T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/246IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
PL14191582T 2005-10-26 2006-10-24 Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta PL2848258T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
EP10181100A EP2332577A1 (en) 2005-10-26 2006-10-24 Novel use of IL-1beta compounds
EP14191582.7A EP2848258B1 (en) 2005-10-26 2006-10-24 Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
EP06826560A EP1940465B1 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies

Publications (1)

Publication Number Publication Date
PL2848258T3 true PL2848258T3 (pl) 2018-06-29

Family

ID=37806690

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14191582T PL2848258T3 (pl) 2005-10-26 2006-10-24 Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
PL06826560T PL1940465T3 (pl) 2005-10-26 2006-10-24 Nowe zastosowanie przeciwciał anty-IL-1beta

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06826560T PL1940465T3 (pl) 2005-10-26 2006-10-24 Nowe zastosowanie przeciwciał anty-IL-1beta

Country Status (28)

Country Link
US (8) US8105587B2 (pl)
EP (5) EP2848258B1 (pl)
JP (4) JP2009513645A (pl)
KR (3) KR101518064B1 (pl)
CN (2) CN102861332A (pl)
AU (1) AU2006306280B2 (pl)
BR (1) BRPI0617830B8 (pl)
CA (3) CA2898369C (pl)
CY (4) CY1113378T1 (pl)
DK (2) DK1940465T3 (pl)
ES (3) ES2944067T3 (pl)
HU (2) HUE036973T2 (pl)
IL (4) IL190545A (pl)
JO (2) JO2826B1 (pl)
LT (3) LT2848258T (pl)
LU (2) LU92326I2 (pl)
MA (1) MA29919B1 (pl)
NO (2) NO345888B1 (pl)
NZ (1) NZ567222A (pl)
PH (2) PH12013501287B1 (pl)
PL (2) PL2848258T3 (pl)
PT (2) PT2848258T (pl)
RU (2) RU2468817C2 (pl)
SI (2) SI2848258T1 (pl)
TN (1) TNSN08189A1 (pl)
TR (1) TR201802449T4 (pl)
TW (3) TWI388335B (pl)
WO (1) WO2007050607A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105587B2 (en) 2005-10-26 2012-01-31 Novartis Ag Methods of treating arthritis using IL-1β binding molecules
US8282922B2 (en) * 2007-05-29 2012-10-09 Novartis Ag Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody
AU2012203932B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
AU2009256072B2 (en) * 2008-06-06 2015-05-28 Xoma (Us) Llc Methods for the treatment of rheumatoid arthritis
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
UY32949A (es) * 2009-10-15 2011-02-28 Abbott Lab Proteínas de unión a il-1
US8841417B2 (en) * 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
KR20130133247A (ko) * 2010-12-21 2013-12-06 애브비 인코포레이티드 Il-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
CN110544517A (zh) 2011-05-10 2019-12-06 雀巢产品有限公司 用于个体化治疗管理的疾病活动性表征方法
US11377656B2 (en) 2016-03-10 2022-07-05 Novartis Ag Chemically modified messenger RNA's
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
AU2018422406A1 (en) * 2018-05-09 2020-11-12 Novartis Ag Use of canakinumab
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
KR20210108422A (ko) 2018-12-21 2021-09-02 노파르티스 아게 IL-1β 결합 항체의 용도
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
US20200369762A1 (en) * 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
US20250099548A1 (en) * 2022-01-10 2025-03-27 Gi Innovation, Inc. Pharmaceutical composition for preventing or treating degenerative brain diseases, containing glucagon-like peptide-1 and interleukin-1 receptor antagonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO1995016353A1 (en) 1993-12-14 1995-06-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Systemic gene treatment of connective tissue diseases
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO2000047619A1 (en) 1999-02-10 2000-08-17 Interleukin Genetics, Inc. Therapeutics and diagnostics based on an il-1b mutation
US6566554B1 (en) * 1999-07-16 2003-05-20 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Aminobenzophenones as inhibitors of IL-1β and TNF-α
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP2329842A3 (en) 2000-05-12 2011-07-27 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
RU2329263C2 (ru) 2000-11-07 2008-07-20 Новартис Аг Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
EP1423432A4 (en) 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
PL374118A1 (pl) 2001-08-07 2005-10-03 Immunex Corporation Receptory interleukiny-1 w leczeniu chorób
ATE556482T1 (de) 2001-12-01 2012-05-15 Iskra Wind Turbines Ltd Synchron-wechselstromgenerator mit einem bremsmechanismus
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
CA2474645C (en) 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
CN101717410B (zh) 2002-02-01 2015-04-29 阿里亚德医药股份有限公司 含磷化合物及其应用
AU2003216227A1 (en) 2002-02-11 2003-09-04 Arkion Life Sciences Llc Purified cytokine inhibitory factor
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
AU2003297740B2 (en) 2002-12-09 2008-09-11 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
CA2509136C (en) * 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CA2545733A1 (en) 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
ES2523147T3 (es) 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
EP2295054A1 (en) 2004-05-27 2011-03-16 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
JP5022216B2 (ja) * 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのil−1アンタゴニストを使用する方法
JP2009501128A (ja) 2005-01-20 2009-01-15 ユニバーシティー オブ ロチェスター 炎症疾患および炎症障害の研究および処置のための組成物および方法
US7851199B2 (en) 2005-03-18 2010-12-14 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
RU2518295C2 (ru) 2005-06-21 2014-06-10 Ксома Текнолоджи Лтд. IL-1бета-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ФРАГМЕНТЫ
US8105587B2 (en) * 2005-10-26 2012-01-31 Novartis Ag Methods of treating arthritis using IL-1β binding molecules

Also Published As

Publication number Publication date
EP3332807A2 (en) 2018-06-13
HUS1800025I1 (hu) 2018-07-30
EP1940465A2 (en) 2008-07-09
DK1940465T3 (da) 2012-10-22
JP6286403B2 (ja) 2018-02-28
IL258983B (en) 2020-10-29
US20150322148A1 (en) 2015-11-12
US8105587B2 (en) 2012-01-31
IL245387A0 (en) 2016-06-30
ES2662420T3 (es) 2018-04-06
EP4218815A2 (en) 2023-08-02
CY1113378T1 (el) 2015-11-04
HK1252316A1 (en) 2019-05-24
EP2332577A1 (en) 2011-06-15
PH12013501287A1 (en) 2016-02-01
CA2898369A1 (en) 2007-05-03
HUE036973T2 (hu) 2018-08-28
IL277406A (en) 2020-11-30
US20170218063A1 (en) 2017-08-03
JP2016020377A (ja) 2016-02-04
CY1120018T1 (el) 2018-12-12
HK1121041A1 (en) 2009-04-17
CY2013046I2 (el) 2015-11-04
RU2468817C2 (ru) 2012-12-10
DK2848258T3 (en) 2018-03-19
LT2848258T (lt) 2018-02-26
LU92326I9 (pl) 2019-01-16
TWI388335B (zh) 2013-03-11
TW201617097A (zh) 2016-05-16
PT2848258T (pt) 2018-03-20
TWI537003B (zh) 2016-06-11
JP2017206552A (ja) 2017-11-24
LTPA2018506I1 (lt) 2018-06-25
EP4218815A3 (en) 2024-03-27
KR20080059598A (ko) 2008-06-30
BRPI0617830B8 (pt) 2021-05-25
US20130171167A1 (en) 2013-07-04
IL245387B (en) 2019-09-26
KR101518064B1 (ko) 2015-05-06
NO345888B1 (no) 2021-09-27
BRPI0617830B1 (pt) 2020-10-20
IL258983A (en) 2018-06-28
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
EP3332807A3 (en) 2018-06-20
ES2389110T3 (es) 2012-10-23
TW201302220A (zh) 2013-01-16
KR20150013834A (ko) 2015-02-05
CN101291693A (zh) 2008-10-22
JP2013166757A (ja) 2013-08-29
AU2006306280A1 (en) 2007-05-03
CY2018018I2 (el) 2018-12-12
JP2009513645A (ja) 2009-04-02
WO2007050607A3 (en) 2007-06-28
US20210147533A1 (en) 2021-05-20
RU2008120625A (ru) 2010-01-20
IL190545A (en) 2016-09-29
TWI626056B (zh) 2018-06-11
CA2626214A1 (en) 2007-05-03
EP2848258B1 (en) 2017-12-13
JP6061747B2 (ja) 2017-01-18
PT1940465E (pt) 2012-10-03
CN102861332A (zh) 2013-01-09
PL1940465T3 (pl) 2013-01-31
CY2013046I1 (el) 2015-11-04
US20080286266A1 (en) 2008-11-20
US20120039910A1 (en) 2012-02-16
CA2963828A1 (en) 2007-05-03
TR201802449T4 (tr) 2018-03-21
EP1940465B1 (en) 2012-08-01
IL190545A0 (en) 2008-11-03
LU92326I2 (fr) 2014-02-05
CA2626214C (en) 2016-06-21
TNSN08189A1 (en) 2009-10-30
PH12020500559A1 (en) 2021-06-14
US20180201674A1 (en) 2018-07-19
SI1940465T1 (sl) 2012-10-30
EP3332807B1 (en) 2023-02-22
RU2571563C2 (ru) 2015-12-20
LTC1940465I2 (lt) 2017-12-11
MA29919B1 (fr) 2008-11-03
JO2826B1 (en) 2014-09-15
SI2848258T1 (en) 2018-03-30
NO20200810A1 (no) 2008-07-22
NO20082344L (no) 2008-07-22
LTC2848258I2 (lt) 2019-08-12
CY2018018I1 (el) 2018-12-12
WO2007050607A2 (en) 2007-05-03
ES2944067T3 (es) 2023-06-19
JOP20140120B1 (ar) 2021-08-17
CN101291693B (zh) 2012-10-03
HK1204767A1 (en) 2015-12-04
KR101749388B1 (ko) 2017-06-20
US8409576B2 (en) 2013-04-02
RU2012133522A (ru) 2014-02-20
TW200803898A (en) 2008-01-16
BRPI0617830A2 (pt) 2011-08-09
LUC00078I2 (fr) 2018-08-14
NZ567222A (en) 2011-07-29
PH12013501287B1 (en) 2016-02-01
AU2006306280B2 (en) 2010-06-17
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
EP2848258A1 (en) 2015-03-18
CA2898369C (en) 2017-06-20

Similar Documents

Publication Publication Date Title
CY2018018I1 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
HUS2100053I1 (hu) Interleukin-13-antitest-készítmény
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
HRP20220755T3 (hr) Anti-gm-csf antitijela i njihova uporaba
DK3295967T3 (da) Sårplejeindretning
CY2016029I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
BRPI0614464A2 (pt) preparação cosmética
PT1943264E (pt) Análogos de oligonucleosídeos incorporando neles 5-azacitosina
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
EP1891999A4 (en) BLOOD CLEANER
BRPI0613622A2 (pt) dispositivo médico
BRPI0818121A2 (pt) diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização
NO20043305D0 (no) Preparation of lodixanol
NO20055643D0 (no) Preparation of lodixanol
EP1906944A4 (en) SKI ANDRIN-B-PREPARATION
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
BRPI0811572A2 (pt) Uso de compostos imunomoduladores no tratamento de doenças alérgicas
FI20055133A0 (fi) Iskulaite
FI20050453A0 (fi) Ihonhoitokoostumus
FI20041385L (fi) Symmetria-akselin määrittäminen
DE602005015944D1 (de) Entspannungsstuhl
FR2880798B1 (fr) Fauteuil roulant
ES1061344Y (es) Pañal
FI20055138A0 (fi) Yhdistetty metsänhakkuu- ja korjuukone
FI20060324L (fi) Palveluiden käytön rajoittaminen